Today’s breakthrough is tomorrow’s standard. Subcutaneous ICD is the first implantable cardiac device to protect patients against both sudden cardiac death and transvenous lead complications, and researchers are continuing to push this technology to the forefront of the electrophysiology field. Join host Wyatt Stahl as he reviews clinical evidence, contextualizes the data and speaks with principal investigators of landmark S-ICD trials — all to cut straight to the heart of this exciting technology. ABOUT THE HOST: Wyatt Stahl is an electrical engineer and a 30-year veteran in cardiac rhythm management, with over a decade of in-field experience alongside both implanters and physicians. Throughout his career, his work has largely focused on electrode-to-tissue long-term maturation and impedance changes with implantable devices.
As S-ICD technology continues to establish itself as a preferred alternative to transvenous cardiac defibrillators, the pre-implant conversation with ICD patients has quickly evolved. Join host Wyatt Stahl and special guest Dr. Martin C. Burke as they trace S-ICD's historic journey in defibrillation therapy from niche to norm—and what it means for patient selection. “I really think that the S-ICD, as a platform, is your go-to platform right off the bat.” Martin C. Burke, electrophysiologist Disclosure: Dr. Burke is a consultant with Boston Scientific. For more information regarding S-ICD and its indications for use, visit bostonscientific.com/sicd. For more information regarding S-ICD usage within the EU, visit bostonscientific.eu/s-icd. For more S-ICD implantation resources and best practices, visit sicdtraining.com.
How can the next generation of implanters take up the mantle of today's S-ICD innovators? For Dr. Martin Burke, the answer comes down to 1) understanding the fundamentals, and 2) practice. Lots of practice. “Your experience and your consistency, and experiencing the operative theater with this device from the prep all the way through to closure, is extremely important to having a successful program.” Martin C. Burke, electrophysiologist Disclosure: Dr. Burke is a consultant with Boston Scientific. For more information regarding S-ICD and its indications for use, visit bostonscientific.com/sicd. For more information regarding S-ICD usage within the EU, visit bostonscientific.eu/s-icd. For more S-ICD implantation resources and best practices, visit sicdtraining.com.
The story of S-ICD technology spans more than three decades, and Dr. Martin Burke has witnessed it all. In the final episode of the interview series, host Wyatt Stahl returns to the earliest days of subcutaneous defibrillation—discovering what the S-ICD of yesterday can teach us about the S-ICD of tomorrow. “I always thought it was funny that we had all these devices that we were putting in subcutaneously, but we never used any of that information towards making sensing better.” Martin C. Burke, electrophysiologist Disclosure: Dr. Burke is a consultant with Boston Scientific. For more information regarding S-ICD and its indications for use, visit bostonscientific.com/sicd. For more information regarding S-ICD usage within the EU, visit bostonscientific.eu/s-icd. For more S-ICD implantation resources and best practices, visit sicdtraining.com.
What does the future hold for S-ICD? When it comes to innovation, the path isn't always clear. But that doesn't mean we won't keep moving forward. “Innovation requires us to have a new way of thinking about the old problem.” Wyatt Stahl, host For more information regarding S-ICD and its indications for use, visit bostonscientific.com/sicd. For more information regarding S-ICD usage within the EU, visit bostonscientific.eu/s-icd. For more S-ICD implantation resources and best practices, visit sicdtraining.com.
If you're wondering when the right time to implement S-ICD into your practice is, you might be asking the wrong question. “All of us learn by mistakes. The question is: do we learn from our mistakes, or do we also learn from the mistakes of others?” Wyatt Stahl, host For more information regarding S-ICD and its indications for use, visit bostonscientific.com/sicd. For more information regarding S-ICD usage within the EU, visit bostonscientific.eu/s-icd. For more S-ICD implantation resources and best practices, visit sicdtraining.com.
The UNTOUCHED study set out to evaluate the IAS rate for S-ICD in a more typical ICD patient population, using standardized programming and enhanced discrimination algorithms. To understand the results, you must know how Nelson Rockefeller died. “Clearly, [S-ICD] is a game changer … rivaling or bettering transvenous systems or anything else that we have out there.” Dr. Michael Gold, UNTOUCHED principal investigator For more information regarding S-ICD and its indications for use, visit bostonscientific.com/sicd. For more information regarding S-ICD usage within the EU, visit bostonscientific.eu/s-icd. For more S-ICD implantation resources and best practices, visit sicdtraining.com.
Host Wyatt Stahl takes on the lingering assumption that S-ICD technology is only a niche therapy
Does S-ICD really stack up against TV-ICD? That was the question posed by the PRAETORIAN Trial, and the answer might surprise you.
S-ICD technology is a breakthrough for implantable cardiac devices, but it's just the latest step in more than 30 years of ICD progress. Host Wyatt Stahl remembers just how far we've come. “I originally doubted the viability of this subcutaneous ICD system. It was only after several in-depth conversations with those early adopters that I started to realize the incredible potential of the S-ICD technology.” Wyatt Stahl, host For more information regarding S-ICD and its indications for use, visit bostonscientific.com/sicd. For more information regarding S-ICD usage within the EU, visit bostonscientific.eu/s-icd. For more S-ICD implantation resources and best practices, visit sicdtraining.com. CRM-1015210-AB CRM-1010905-AA (Audio)
© 2020-2025 Ivy Podcast Discovery LLC
